ID   MEG-01
AC   CVCL_0425
SY   Meg-01; MEG01; Meg01
DR   BTO; BTO:0002581
DR   CLO; CLO_0007668
DR   EFO; EFO_0002232
DR   MCCL; MCC:0000322
DR   CLDB; cl3432
DR   CLDB; cl3433
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2021
DR   BCRC; 60238
DR   BCRJ; 0262
DR   BioSample; SAMN01821577
DR   BioSample; SAMN01821648
DR   BioSample; SAMN01821734
DR   BioSample; SAMN03471278
DR   BioSample; SAMN10988184
DR   cancercelllines; CVCL_0425
DR   CCRID; 1101HUM-PUMC000521
DR   CCRID; 3101HUMTCHu197
DR   Cell_Model_Passport; SIDM00526
DR   ChEMBL-Cells; CHEMBL3308539
DR   ChEMBL-Targets; CHEMBL2366084
DR   Cosmic; 787503
DR   Cosmic; 908126
DR   Cosmic; 924042
DR   Cosmic; 1026578
DR   Cosmic; 1070702
DR   Cosmic; 1078723
DR   Cosmic; 1516634
DR   Cosmic; 1523830
DR   Cosmic-CLP; 908126
DR   DepMap; ACH-000072
DR   DSMZ; ACC-364
DR   DSMZCellDive; ACC-364
DR   ECACC; 94012401
DR   EGA; EGAS00001000978
DR   GDSC; 908126
DR   GEO; GSM482498
DR   GEO; GSM887307
DR   GEO; GSM888383
DR   GEO; GSM1374669
DR   GEO; GSM1670093
DR   IARC_TP53; 21491
DR   ICLC; HTL96017
DR   IGRhCellID; MEG01
DR   JCRB; IFO50151
DR   LiGeA; CCLE_381
DR   LINCS_LDP; LCL-1110
DR   Lonza; 959
DR   PharmacoDB; MEG01_913_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0425
DR   PubChem_Cell_line; CVCL_0425
DR   Wikidata; Q54905035
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1742484;
RX   PubMed=2998511;
RX   PubMed=3332852;
RX   PubMed=9738977;
RX   PubMed=10071072;
RX   PubMed=15843827;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20809971;
RX   PubMed=22460905;
RX   PubMed=27277069;
RX   PubMed=27397505;
RX   PubMed=30285677;
RX   PubMed=30332548;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=32180119;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Characteristics: Can be induced to differentiate into megakaryocytes after application of 12-O-tetradecanoyl-13-phorbol acetate (TPA) or valproic acid (VPA) (PubMed=1742484; PubMed=30332548).
CC   Doubling time: 36-48 hours (PubMed=2998511); ~35 hours (DSMZ=ACC-364).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=15843827; PubMed=20809971; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His233del (c.697_699delCAC); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.14%; Native American=0%; East Asian, North=79.13%; East Asian, South=17.4%; South Asian=0%; European, North=0%; European, South=2.33% (PubMed=30894373).
CC   Misspelling: Mego-1; Note=Occasionally.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): ATCC; Cosmic-CLP; DSMZ; ECACC; JCRB
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 8
ST   D16S539: 9
ST   D18S51: 18,22
ST   D19S433: 14,16
ST   D21S11: 29
ST   D2S1338: 19
ST   D3S1358: 15
ST   D5S818: 13
ST   D7S820: 11
ST   D8S1179: 14,15
ST   FGA: 26
ST   Penta D: 11,13
ST   Penta E: 15
ST   TH01: 7
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   55Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 42
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1742484; DOI=10.1182/blood.V78.12.3168.3168;
RA   Murate T., Hotta T., Tsushita K., Suzuki M., Yoshida T., Saga S.,
RA   Saito H., Yoshida S.;
RT   "Aphidicolin, an inhibitor of DNA replication, blocks the TPA-induced
RT   differentiation of a human megakaryoblastic cell line, MEG-O1.";
RL   Blood 78:3168-3177(1991).
//
RX   PubMed=2998511; DOI=10.1182/blood.V66.6.1384.1384;
RA   Ogura M., Morishima Y., Ohno R., Kato Y., Hirabayashi N., Nagura H.,
RA   Saito H.;
RT   "Establishment of a novel human megakaryoblastic leukemia cell line,
RT   MEG-01, with positive Philadelphia chromosome.";
RL   Blood 66:1384-1392(1985).
//
RX   PubMed=3332852; DOI=10.1016/S0950-3536(87)80037-9;
RA   Keating A.;
RT   "Ph positive CML cell lines.";
RL   Baillieres Clin. Haematol. 1:1021-1029(1987).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=10071072; DOI=10.1016/s0145-2126(98)00171-4;
RA   Drexler H.G., MacLeod R.A.F., Uphoff C.C.;
RT   "Leukemia cell lines: in vitro models for the study of Philadelphia
RT   chromosome-positive leukemia.";
RL   Leuk. Res. 23:207-215(1999).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20809971; DOI=10.1186/1755-8166-3-15;
RA   Virgili A., Nacheva E.;
RT   "Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in
RT   chronic myeloid leukaemia: a FISH mapping study of CML patients and
RT   cell lines.";
RL   Mol. Cytogenet. 3:15.1-15.12(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=27277069; DOI=10.1160/TH15-11-0891;
RA   Wright J.R., Amisten S., Goodall A.H., Mahaut-Smith M.P.;
RT   "Transcriptomic analysis of the ion channelome of human platelets and
RT   megakaryocytic cell lines.";
RL   Thromb. Haemost. 116:272-284(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30332548; DOI=10.1080/09537104.2018.1528344;
RA   Dhenge A., Kuhikar R., Kale V., Limaye L.S.;
RT   "Regulation of differentiation of MEG01 to megakaryocytes and
RT   platelet-like particles by valproic acid through Notch3 mediated actin
RT   polymerization.";
RL   Platelets 30:780-795(2019).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=32180119; DOI=10.1007/s12185-020-02853-6;
RA   Saito H., Hayakawa M., Kamoshita N., Yasumoto A., Suzuki-Inoue K.,
RA   Yatomi Y., Ohmori T.;
RT   "Establishment of a megakaryoblastic cell line for conventional
RT   assessment of platelet calcium signaling.";
RL   Int. J. Hematol. 111:786-794(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//